Business Overview: MiNK Therapeutics, Inc. (NASDAQ: INKT)

---

Executive Summary

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies — a cell type that can bridge innate and adaptive immunity — for cancer and severe inflammatory lung disease. Headquartered at 149 Fifth Avenue in New York City, MiNK was spun out of Agenus Inc., which remains a significant shareholder and continues to provide MiNK's legal, finance, IT, and HR functions under a services agreement.

MiNK has no approved products and generates no product or royalty revenue; it matters for its differentiated, closed-system manufacturing platform — producing iNKT cells over 99% pure — and for early clinical signals in two very different settings: acute respiratory failure from severe pneumonia, and gastroesophageal cancers in combination with Agenus's checkpoint antibodies.

---

1. Core Business Model & How They Work

As a clinical-stage cell-therapy company, MiNK's "business model" is translating a differentiated cell platform into clinical proof-of-concept data that can support partnerships, licensing deals, or an eventual approval and commercial launch.

[ Donor-Derived iNKT Cell Isolation ] ➡️ [ Closed-System cGMP Expansion (Lexington, MA) ] ➡️ [ >99% Pure iNKT Cell Product ] ➡️ [ Clinical Trials (Oncology + Pulmonary) ] ➡️ [ Partnership / Licensing / Approval ]

Key Operational Drivers

1. Off-the-shelf allogeneic model: unlike autologous CAR-T therapies that must be manufactured per patient, MiNK's donor-derived iNKT cells are designed to be administered without patient-specific manufacturing, aiming for faster, cheaper treatment access.
2. Dual-indication strategy: the lead candidate, agenT-797, is being developed simultaneously in oncology (solid tumors, gastroesophageal cancer) and in acute respiratory failure/severe pneumonia — a hedge against single-indication clinical risk.
3. Agenus relationship: access to Agenus's immuno-oncology antibodies (botensilimab, balstilimab) for combination studies, plus shared back-office infrastructure that keeps MiNK's own headcount (15 full-time employees) very lean.
4. External collaborations: partnerships with C-Further (pediatric TCR-PRAME candidate), Autonomous Therapeutics (encrypted RNA research), and Immunoscape (TCR-based therapies) extend the pipeline without MiNK bearing full R&D cost alone.

---

2. Business Segments

MiNK operates as a single clinical-stage biotechnology business with no reportable segments; all activity falls under pipeline research and development.

---

3. Product Portfolio

---

4. Competitive Landscape

MiNK competes across several overlapping cell-therapy categories:

• Autologous CAR-T / TCR developers (large pharma and biotech) — generally better capitalized, with approved products already on the market in some indications.
• Other allogeneic and iNKT-focused developers — direct platform competitors pursuing off-the-shelf cell therapies.
• NK and γδ T-cell developers — adjacent innate-immunity approaches targeting overlapping cancer indications.
• Non-cell-therapy approaches to ARDS — stem-cell and pharmacological candidates competing for the same acute respiratory failure opportunity, a space with few dedicated cell-therapy entrants, giving MiNK relatively less direct competition there than in oncology.

MiNK's differentiation rests on its iNKT-specific platform and dual oncology/pulmonary strategy, not on scale — essentially all named competitor categories have greater financial and technical resources.

---

5. Strategic Strengths & Risks

Strengths

• Differentiated, high-purity (>99%) off-the-shelf iNKT manufacturing platform, reducing the per-patient cost and timeline burden typical of autologous cell therapies.
• Encouraging early survival data in a difficult-to-treat acute respiratory failure population, a less crowded competitive field than oncology cell therapy.
• Lean cost structure (15 employees) enabled by shared services with Agenus, extending cash runway.
• Multiple external collaborations (C-Further, Autonomous Therapeutics, Immunoscape) diversify pipeline shots without proportional cash outlay.

Risks

• No approved products or revenue: the company is entirely dependent on clinical success and future financing or partnering.
• Small company, small market value: non-affiliate market value of only $10.9 million as of mid-2025, reflecting a thin capital base relative to the cost of running Phase 2 trials.
• Dependence on Agenus: shared back-office functions and IP licensing tie MiNK's operational continuity to Agenus's own stability and strategic priorities.
• Widening losses: net loss grew to $12.5 million in 2025 from $10.8 million in 2024, against a large accumulated deficit of $156.7 million.
• Crowded oncology cell-therapy field: the oncology indications face numerous better-funded CAR-T, TCR, and checkpoint-inhibitor competitors.

---

6. Financial Overview

---

7. Summary Conclusion

MiNK Therapeutics is a capital-constrained, clinical-stage cell-therapy company whose real asset is a differentiated, high-purity, off-the-shelf iNKT manufacturing platform rather than any near-term revenue stream. Its dual bet — on acute respiratory failure, where early survival data stand out against a thin competitive field, and on oncology, where it faces deep-pocketed CAR-T and checkpoint-inhibitor rivals — gives it two distinct paths to clinical validation, but both still require successful trial readouts and additional financing to reach commercialization. The central risk is runway: with a market value under $11 million and losses still growing, MiNK's ability to carry agenT-797 through Phase 2 and beyond will likely depend on new capital, a partnership, or continued support from Agenus.